Biocon wins OK for Herceptin biosimilar; Dicerna, Argos and NephroGenex set IPO terms;

@FierceBiotech: Alzheimer's expert claims he was wooed into biotech insider scandal. Article | Follow @FierceBiotech

@JohnCFierce: First Pfizer, now J&J. Jim Allison is a big draw. Industry giants join MD Anderson's star team for immunotherapies. Story | Follow @JohnCFierce

@DamianFierce: If Amarin's latest Vascepa appeal fails, it has two more FDA rungs to climb, agency says. More | Follow @DamianFierce

@EmilyMFierce: Cleveland Clinic researchers find protein responsible for amyloid buildup, memory loss in Alzheimer's. Story | Follow @EmilyMFierce

> India's Biocon and Mylan ($MYL) have won approval for a biosimilar of Herceptin and plan to launch it in the subcontinent next month. Story

> Dicerna Pharmaceuticals has set its terms, laying out plans to sell 5 million shares for $11 to $13 a share. Story

> Durham, NC-based Argos Therapeutics is looking to raise about $60 million from the sale of 4.1 million shares in an IPO priced at $13 to $15 a share. Report

> NephroGenex has set terms for its IPO, planning to sell 3.1 million shares at $12 to $14 a share. At the mid-range the offering would raise about $40 million. Story

Medical Device News

@FierceMedDev: J&J's Q4 looked great for orthopedics, but less so for diabetes and Dx. More | Follow @FierceMedDev

@MarkHFierce: Covidien said slow market growth led to its decision to abandon a renal denervation program. Story | Follow @MarkHFierce

@MichaelGFierce: Myriad will sell breast cancer Dx from Siemens spinoff in Europe. Item | Follow @MichaelGFierce

@EmilyWFierce: Boston physician questions medical devices used during minimally invasive hysterectomies. Article | Follow @EmilyWFierce

> Tandem expands its voluntary recall of the t:slim insulin pump. Report

> Medtronic's transcatheter heart valve scores early FDA approval. News

Pharma News

@FiercePharma: Saline shortage: FDA works with Baxter, Hospira and Braun. More | Follow @FiercePharma

@TracyStaton: J&J, Glaxo tops in pharma social media, but smaller companies rate highly, too. Report | Follow @TracyStaton

@EricPFierce: Roche says in an email that the temporary shortage of Tamiflu is over. The FDA says so too. More | Follow @EricPFierce

@CarlyHFierce: Forest's Q3 numbers are out - take a look. Release | Follow @CarlyHFierce

> Turbocharged pharma growth drives J&J's 2013 sales to $71B. Report

> Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics. News

> NuPathe nixes Endo's buyout offer to hook up with Teva. Story

Pharma Manufacturing News

> Shire has a partially built plant for sale after unloading Dermagraft. News

> Aurobindo deal with Actavis accelerates its expansion of sterile injectables biz. Story

> FDA recall questions the sterility of eye drops made in Vietnam. Report

> Saline shortage: FDA works with Baxter, Hospira and Braun. More

> Genentech resolves plant backup quickly but timing was bad. Article

> Novartis manufacturing gets more jobs in major restructuring. Item

Biotech Research News

> Omnibus bill to restore $1B in funding to NIH. Story

> Microparticle therapy restores damaged tissue after a heart attack. Report

> AstraZeneca, Bristol-Myers bestow $5M on diabetes research program. Item

> Existing antiviral drug could treat H7N9 flu. Article

> Innovimmune inhibitor prevents multiple sclerosis in mice. More

> Alzheimer's research blames a protein for amyloid buildup, memory loss. News

CRO News

> Patheon soars in its last year as a public CMO. Item

> AMRI: Burlington 'money pit' is now a springboard. More

> Device CRO NAMSA rolls into the U.K. with Medvance buyout. Article

> Harlan targets India with latest animal model expansion. Story

> Parexel ups its expectations after a late-year stumble. Report

> BioClinica preps for another merger as CRO consolidation marches on. Article

Biotech IT News

> Record year at PLOS ONE creates new challenges for data scientists. Item

> Regeneron to sequence 100K exomes and link data to EHRs to speed drug discovery. Story

> BioClinica to go through second merger since being taken private last year. More

> European Union makes $40M available for development of bioinformatics tools. Article

> Illumina hits the $1,000 genome mark with a big-data 'cannonball.' Story

> FDA publishes a slice of social media guidance as the deadline for a full policy nears. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.